An observational study in Hemophilia A, sponsored by Octapharma. Terminated at 3 sites in Canada. Open to male participants. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by Octapharma · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hemophilia A by Octapharma — 3 open to participants now, 3 under way, none of them phase 3. Hemophilia A · Octapharma.
Among the 15 studies in Hemophilia A by Octapharma, this one is one of 2 that started in 2018, is one of 3 observational ones, and was the 10th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →3 of the 15 studies in Hemophilia A by Octapharma are open now, in 12 countries. Recruiting first, the newest first:
Octapharma · Sites in United States, Finland, France and 7 more countries
Ages 12+ · Women only
Octapharma · Sites in United States, Croatia, Finland and 8 more countries
Ages 12+ · Men only
Octapharma · Sites in United States, Argentina, Azerbaijan and 15 more countries
By country, each count listing its studies:
Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.
This study: male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 8 · Phase 4 2
First in 2010; this study’s year is marked. 2 started in 2018.
This study's enrollment of 14 is below the median of 81 across 310 observational studies indexed under Hemophilia A.
Median enrollment 34 across the 12 interventional studies, 80 across the 3 observational. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Octapharma is the lead sponsor of 71 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 16 (94%) have results posted.
2 of the studies in Hemophilia A by Octapharma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05935358OctapharmaNuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study | 2026-12 |
| NCT05936580OctapharmaNuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Hemophilia A by Octapharma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Uncontrolled, multi-centre, non-interventional study with a prospective and a retrospective cohort, to evaluate the efficacy of Wilate or Nuwiq in achieving complete or partial immune tolerance induction (ITI) success in severe and moderate haemophilia A patients with inhibitors
A total of at least 80 patients were planned, at least 40 in the prospective cohort and 40 in the retrospective cohort. Due to study termination, only 14 patients were enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For patients in the prospective cohort:
For patients in the retrospective cohort:
Exclusion Criteria:
Patients who meet any of the following criteria are not eligible for the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Evaluable haemophilia A patients with an inhibitor against FVIII enrolled prospectively
Drug: Wilate or Nuwiq
Evaluable haemophilia A patients with an inhibitor against FVIII enrolled retrospectively
Drug: Wilate or Nuwiq
Wilate or Nuwiq administered via intravenous injection
Also known as: Wilate: Human von Willebrand factor / human coagulation factor VIII. Nuwiq: recombinant factor VIII (rhFVIII)
Number of Moderate and Severe Haemophilia A Patients With Inhibitors Achieving Complete or Partial Immune Tolerance Induction (ITI) Success
ITI success will be determined using predefined success criteria to analyze the proportion of patients achieving complete or partial ITI success. Complete success is defined by achieving all of the following variables: 1) Inhibitor titre \<0.6BU (at least 2 separate blood samplings) assessed using the modified Bethesda assay; 2) Incremental in vivo recovery (IVR) of FVIII in the normal range (≥66% of normal); 3) FVIII half-life ≥6 hours Wilate infusion. Partial success is defined as two of the three criteria being met, whilst partial response is defined as one of the three criteria being met. Partial failure is defined as none of the three criteria are met, but the inhibitor titre has decreased to \<5 BU; complete failure is defined as none of the three criteria are met, and the inhibitor titre is still ≥5 BU.
Time frame: From ITI start until termination of study, a maximum of 2 years
Time Necessary to Achieve Complete or Partial ITI Success
Time to achieve complete or partial ITI success will be determined using predefined success criteria. Complete success is defined by achieving all of the following variables: 1) Inhibitor titre \<0.6 BU (at least 2 separate blood samplings) assessed using the modified Bethesda assay; 2) Incremental IVR of FVIII in the normal range (≥66% of normal) ; 3) FVIII half-life ≥6 hours. Wilate infusion. Partial success is defined as two of the three criteria being met, whilst partial response is defined as one of the three criteria being met. Partial failure is defined as none of the three criteria are met, but the inhibitor titre has decreased to \<5 BU; complete failure is defined as none of the three criteria are met, and the inhibitor titre is still ≥5 BU. 0 participants analysed for this outcome due to termination of study.
Time frame: A maximum period of 5 years from ITI start
In Case of Complete or Partial ITI Success, Duration of Immune Tolerance
Time from start of ITI success to end of study period
Time frame: A maximum period of 5 years from ITI start
Bleeding Frequency While on Wilate or Nuwiq ITI Treatment
Bleeding episodes occurring during the study period will be documented by the patient or their parents in a patient study diary.
Time frame: A maximum period of 5 years from ITI start
Association of Inhibitor Titres With the Probability of ITI Success
Inhibitor titre will be assessed at the start of and throughout ITI treatment, including peak inhibitor titres, with the probability of ITI success. ITI success will be determined using predefined success criteria. Complete success is defined by achieving all of the following variables: 1) Inhibitor titre \<0.6 BU (at least 2 separate blood samplings) assessed using the modified Bethesda assay; 2) Incremental IVR of FVIII in the normal range (≥66% of normal) ; 3) FVIII half-life ≥6 hours. Wilate or Nuwiq infusion. Partial success is defined as two of the three criteria being met, whilst partial response is defined as one of the three criteria being met. Partial failure is defined as none of the three criteria are met, but the inhibitor titre has decreased to \<5 BU; complete failure is defined as none of the three criteria are met, and the inhibitor titre is still ≥5 BU.
Time frame: A maximum period of 5 years from ITI start
Use of Bypassing Agents Before and During ITI Treatment With Wilate or Nuwiq
Use of bypassing agents is at the discretion of the Investigator, either to treat bleeding or to provide prophylactic therapy. As long as the patient's inhibitor level is ≥0.6 Bethesda units (BU), treatment of BEs may, in addition to FVIII treatment, require the administration of activated prothrombin complex concentrates (aPCC) or recombinant FVIIa.
Time frame: 12 months before the start of ITI with Wilate or Nuwiq to a maximum of 5 years from starting ITI with Wilate or Nuwiq
Use of Emicizumab (Hemlibra) During ITI Treatment With Wilate or Nuwiq
The dosing and frequency of emicizumab (Hemlibra) used is at the discretion of the Investigator. As a general guidance, the recommended dose is 3mg/kg once weekly for the first 4 weeks, followed by 1.5mg/kg once weekly, administered as a subcutaneous injection, as per the product monograph.
Time frame: A maximum period of 5 years from ITI start
Relapse Rate Following Complete or Partial Successful ITI Using Wilate or Nuwiq
Reoccurrence of \>0.6 BU in at least 2 consecutive blood samples after having reached the prophylactic treatment phase; a further ITI initiation (re-start) with Wilate or Nuwiq is at the discretion of the Investigator.
Time frame: A maximum period of 5 years from ITI start
Time to Relapse Following Complete or Partial Successful ITI Using Wilate or Nuwiq
Time to reoccurrence of \>0.6 BU in at least 2 consecutive blood samples after having reached the prophylactic treatment phase; a further ITI initiation (re-start) with Wilate or Nuwiq is at the discretion of the Investigator.
Time frame: A maximum period of 5 years from ITI start
Adherence With the ITI Regimen
During ITI, any injections of Wilate or Nuwiq will be recorded in the patient study diary. The treating physician will review and verify the information provided by the patient.
Time frame: A maximum period of 5 years from ITI start
| Milestone | Wilate® Retrospective Cohort | Wilate® Prospective Cohort |
|---|---|---|
| Started | 8 | 6 |
| Completed | 6 | 6 |
| Not completed | 2 | 0 |
| Withdrew: Switched to alternative treatment | 1 | 0 |
| Withdrew: Experienced a better response with recombinant activated factor vii (rfviia) | 1 | 0 |
ITI success will be determined using predefined success criteria to analyze the proportion of patients achieving complete or partial ITI success. Complete success is defined by achieving all of the following variables: 1) Inhibitor titre \<0.6BU (at least 2 separate blood samplings) assessed using the modified Bethesda assay; 2) Incremental in vivo recovery (IVR) of FVIII in the normal range (≥66% of normal); 3) FVIII half-life ≥6 hours Wilate infusion. Partial success is defined as two of the three criteria being met, whilst partial response is defined as one of the three criteria being met. Partial failure is defined as none of the three criteria are met, but the inhibitor titre has decreased to \<5 BU; complete failure is defined as none of the three criteria are met, and the inhibitor titre is still ≥5 BU.
| Participants | Wilate® Respective Cohort | Wilate® Prospective Cohort |
|---|---|---|
| Complete success | 7 | 0 |
| Partial success | 0 | 0 |
| Partial failure | 0 | 0 |
| Complete failure | 1 | 0 |
Time to achieve complete or partial ITI success will be determined using predefined success criteria. Complete success is defined by achieving all of the following variables: 1) Inhibitor titre \<0.6 BU (at least 2 separate blood samplings) assessed using the modified Bethesda assay; 2) Incremental IVR of FVIII in the normal range (≥66% of normal) ; 3) FVIII half-life ≥6 hours. Wilate infusion. Partial success is defined as two of the three criteria being met, whilst partial response is defined as one of the three criteria being met. Partial failure is defined as none of the three criteria are met, but the inhibitor titre has decreased to \<5 BU; complete failure is defined as none of the three criteria are met, and the inhibitor titre is still ≥5 BU. 0 participants analysed for this outcome due to termination of study.
No measurements were reported for this outcome.
Time from start of ITI success to end of study period
No measurements were reported for this outcome.
Bleeding episodes occurring during the study period will be documented by the patient or their parents in a patient study diary.
No measurements were reported for this outcome.
Inhibitor titre will be assessed at the start of and throughout ITI treatment, including peak inhibitor titres, with the probability of ITI success. ITI success will be determined using predefined success criteria. Complete success is defined by achieving all of the following variables: 1) Inhibitor titre \<0.6 BU (at least 2 separate blood samplings) assessed using the modified Bethesda assay; 2) Incremental IVR of FVIII in the normal range (≥66% of normal) ; 3) FVIII half-life ≥6 hours. Wilate or Nuwiq infusion. Partial success is defined as two of the three criteria being met, whilst partial response is defined as one of the three criteria being met. Partial failure is defined as none of the three criteria are met, but the inhibitor titre has decreased to \<5 BU; complete failure is defined as none of the three criteria are met, and the inhibitor titre is still ≥5 BU.
No measurements were reported for this outcome.
Use of bypassing agents is at the discretion of the Investigator, either to treat bleeding or to provide prophylactic therapy. As long as the patient's inhibitor level is ≥0.6 Bethesda units (BU), treatment of BEs may, in addition to FVIII treatment, require the administration of activated prothrombin complex concentrates (aPCC) or recombinant FVIIa.
No measurements were reported for this outcome.
The dosing and frequency of emicizumab (Hemlibra) used is at the discretion of the Investigator. As a general guidance, the recommended dose is 3mg/kg once weekly for the first 4 weeks, followed by 1.5mg/kg once weekly, administered as a subcutaneous injection, as per the product monograph.
No measurements were reported for this outcome.
Reoccurrence of \>0.6 BU in at least 2 consecutive blood samples after having reached the prophylactic treatment phase; a further ITI initiation (re-start) with Wilate or Nuwiq is at the discretion of the Investigator.
No measurements were reported for this outcome.
Time to reoccurrence of \>0.6 BU in at least 2 consecutive blood samples after having reached the prophylactic treatment phase; a further ITI initiation (re-start) with Wilate or Nuwiq is at the discretion of the Investigator.
No measurements were reported for this outcome.
During ITI, any injections of Wilate or Nuwiq will be recorded in the patient study diary. The treating physician will review and verify the information provided by the patient.
No measurements were reported for this outcome.
Collected over Adverse drug reactions were monitored throughout the study from first treatment through to study termination, a maximum of 2 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Wilate® Retrospective Cohort | 0/8 (0%) | 1/8 (12.5%) | 0/8 (0%) |
| Wilate® Prospective Cohort | 0/6 (0%) | 1/6 (16.7%) | 1/6 (16.7%) |
| Event | Wilate® Retrospective Cohort | Wilate® Prospective Cohort |
|---|---|---|
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 0/8 | 1/6 |
| Device-related infectionInfections and infestations | 1/8 | 0/6 |
| GastroenteritisGastrointestinal disorders | 1/8 | 0/6 |
| Bronchial hyperreactivityRespiratory, thoracic and mediastinal disorders | 1/8 | 0/6 |
| Event | Wilate® Retrospective Cohort | Wilate® Prospective Cohort |
|---|---|---|
| PyrexiaInfections and infestations | 0/8 | 1/6 |
| Age, Continuous(years) | Wilate® Retrospective Cohort | Wilate® Prospective Cohort | Total |
|---|---|---|---|
| Mean | 10.6 ± 5.2 | 14.8 ± 7.3 | 12.4 ± 6.1 |
| Sex: Female, Male(Participants) | Wilate® Retrospective Cohort | Wilate® Prospective Cohort | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 8 | 6 | 14 |
| Race/Ethnicity, Customized(Participants) | Wilate® Retrospective Cohort | Wilate® Prospective Cohort | Total |
|---|---|---|---|
| Asian | 1 | 0 | 1 |
| White | 5 | 4 | 9 |
| Other | 1 | 2 | 3 |
| Missing | 1 | 0 | 1 |
| Blood type(Participants) | Wilate® Retrospective Cohort | Wilate® Prospective Cohort | Total |
|---|---|---|---|
| O | 3 | 2 | 5 |
| A | 2 | 2 | 4 |
| B | 1 | 0 | 1 |
| AB | 1 | 2 | 3 |
| Missing | 1 | 0 | 1 |
| Severity of hemophilia A(Participants) | Wilate® Retrospective Cohort | Wilate® Prospective Cohort | Total |
|---|---|---|---|
| Mild | 5 | 2 | 7 |
| Moderate | 1 | 1 | 2 |
| Severe | 1 | 3 | 4 |
| Missing | 1 | 0 | 1 |
| FVIII mutation(Participants) | Wilate® Retrospective Cohort | Wilate® Prospective Cohort | Total |
|---|---|---|---|
| Intron 22 Inversion | 3 | 3 | 6 |
| Intron 1 Inversion | 1 | 0 | 1 |
| Missense mutations | 0 | 1 | 1 |
| Unknown | 3 | 2 | 5 |
| Missing | 1 | 0 | 1 |
| Previous inhibitor treatment(Participants) | Wilate® Retrospective Cohort | Wilate® Prospective Cohort | Total |
|---|---|---|---|
| Yes | 6 | 4 | 10 |
| No | 2 | 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2018 to primary completion in Nov 2020, 28 months.
Results were first posted in Aug 2024, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.